Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-744-6 | CAS number: 110-18-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.35 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 75
- Dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 26.5 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. A corrected starting point (inhalation NOAEC) of 26.5 mg/m3 can be calculated based on activity and breathing rate, and for the relative extent of oral (50%) and inhalation absorption (100%).
- AF for dose response relationship:
- 1
- Justification:
- Default value: starting point is a NOAEL
- AF for differences in duration of exposure:
- 6
- Justification:
- Default value: extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not required: already accounted for
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- Default value: workers
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: good quality database
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.1 mg/kg bw/day
- Most sensitive endpoint:
- effect on fertility
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 300
- Dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 30 mg/kg bw/day is calculated.
- AF for dose response relationship:
- 1
- Justification:
- Default value: starting point is a NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- Default value: extrapolation from sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: starting point is derived from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value:
- AF for intraspecies differences:
- 5
- Justification:
- Default value: workers
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: good quality database
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - workers
TMEDA has a harmonised classification for acute oral and acute inhalation toxicity in Category 4; no data are available for acute dermal toxicity. TMEDA has a harmonised classification for skin irritation in Category 1B. No skin sensitisation data are available. TMEDA was not genotoxic in two Ames tests or in a study of mammalian cell mutation. A positive result is reported in vitro in a study of chromosomal aberration, but only at concentrations exceeding the limit concentration. Negative results are reported in vivo in two mouse bone marrow micronucleus assays. TMEDA is therefore concluded not to be genotoxic. The OECD 422 screening study determined a NOAEL of 30 mg/kg bw/day. This oral NOAEL is used as the starting point for DNEL derivation.
DNEL derivation
Inhalation DNELs
Systemic DNELs
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. A corrected starting point (inhalation NOAEC) of 26.5 mg/m3 can be calculated based on activity and breathing rate, and for the relative extent of oral (50%) and inhalation absorption (100%). Individual assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure), 1 (for allometric scaling), 2.5 (for other interspecies differences), 5 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 75. Application of the overall assessment factor to the corrected starting point results in a long-term systemic inhalation DNEL of 0.35 mg/m3.
TMEDA is acutely toxic and has a harmonised classification for acute inhalation toxicity in Category 4. This classification does not result in TMEDA being assigned to any hazard band according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). A short-term systemic inhalation DNEL is not required.
Local DNELs
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). Long-term and short-term local inhalation DNELs are not derived.
Dermal DNELs
Systemic DNELs
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 30 mg/kg bw/day is calculated. Individual assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 5 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 300. Application of the overall assessment factor to the corrected starting point results in a long-term systemic dermal DNEL of 0.1 mg/kg bw/day.
No acute dermal toxicity data are available. TMEDA is acutely toxic and has harmonised classification for acute oral and inhalation toxicity in Category 4. This classification does not result in TMEDA being assigned to any hazard band according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). A short-term systemic dermal DNEL is not required.
Local DNELs
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). Long-term and short-term local dermal DNELs are not derived.
Hazard for the eyes
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016).
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.1 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 150
- Dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 13 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. A corrected starting point (inhalation NOAEC) of 13 mg/m3 can be calculated based on breathing rate, and for the relative extent of oral (50%) and inhalation absorption (100%).
- AF for dose response relationship:
- 1
- Justification:
- Default value: starting point is a NOAEL
- AF for differences in duration of exposure:
- 6
- Justification:
- Default value: extrapolation from sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not required: already accounted for
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: good quality database
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.05 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 600
- Dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 30 mg/kg bw/day is calculated.
- AF for dose response relationship:
- 1
- Justification:
- Default value: starting point is a NOAEL
- AF for differences in duration of exposure:
- 6
- Justification:
- Default value: extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: starting point is from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value:
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: good quality database
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.05 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 600
- Dose descriptor starting point:
- NOAEL
- Value:
- 30 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
Correction of the starting point is not required.
- AF for dose response relationship:
- 1
- Justification:
- Default value: starting point is a NOAEL
- AF for differences in duration of exposure:
- 6
- Justification:
- Default value: extrapolation from a sub-acute study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: starting point is from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value:
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: good quality database
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - General Population
TMEDA has a harmonised classification for acute oral and acute inhalation toxicity in Category 4; no data are available for acute dermal toxicity. TMEDA has a harmonised classification for skin irritation in Category 1B. No skin sensitisation data are available. TMEDA was not genotoxic in two Ames tests or in a study of mammalian cell mutation. A positive result is reported in vitro in a study of chromosomal aberration, but only at concentrations exceeding the limit concentration. Negative results are reported in vivo in two mouse bone marrow micronucleus assays. TMEDA is therefore concluded not to be genotoxic. The OECD 422 screening study determined a NOAEL of 30 mg/kg bw/day. This oral NOAEL is used as the starting point for DNEL derivation.
DNEL derivation
Inhalation DNELs
Systemic DNELs
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. A corrected starting point (inhalation NOAEC) of 26.5 mg/m3 can be calculated based on breathing rate, and for the relative extent of oral (50%) and inhalation absorption (100%). Individual assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure), 1 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 150. Application of the overall assessment factor to the corrected starting point results in a long-term systemic inhalation DNEL of 0.1 mg/m3.
TMEDA is acutely toxic and has a harmonised classification for acute inhalation toxicity in Category 4. This classification does not result in TMEDA being assigned to any hazard band according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). A short-term systemic inhalation DNEL is not required.
Local DNELs
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). Long-term and short-term local inhalation DNELs are not derived.
Dermal DNELs
Systemic DNELs
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 30 mg/kg bw/d is calculated. Individual assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 600. Application of the overall assessment factor to the corrected starting point results in a long-term systemic dermal DNEL of 0.05 mg/kg bw/day.
No acute dermal toxicity data are available. TMEDA is acutely toxic and has harmonised classification for acute oral and inhalation toxicity in Category 4. This classification does not result in TMEDA being assigned to any hazard band according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). A short-term systemic dermal DNEL is not required.
Local DNELs
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). Long-term and short-term local dermal DNELs are not derived.
Oral DNELs
The relevant starting point is the NOAEL of 30 mg/kg bw/day from the oral OECD 422 screening study with TMEDA. Correction of the starting point is not required. Individual assessment factors of 1 (for dose-response relationship), 6 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 600. Application of the overall assessment factor to the corrected starting point results in a long-term systemic dermal DNEL of 0.05 mg/kg bw/day.
TMEDA is acutely toxic and has harmonised classification for acute oral toxicity in Category 4. This classification does not result in TMEDA being assigned to any hazard band according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016). A short-term systemic dermal DNEL is not required.
Hazard for the eyes
TMEDA has a harmonised classification for skin corrosion in Category 1B and is therefore defined as a moderate hazard according to Table E.3-1 of the ECHA Guidance on Information Requirements and Chemical Safety Assessment (v2.0, May 2016).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.